Surgalign Holdings Inc., a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, announced the commercial launch and the completion of the first surgery of ViBone Moldable in the US. The first implantation was completed by Dr. Adam Crowl, at OrthoVirgina in Midlothian, Va. ViBone Moldable is the newest orthobiologics solution of Surgalign’s bone graft portfolio to support spinal fusion, which currently include ViBone and other advanced bone graft solutions.
 
ViBone Moldable, provided by Aziyo Biologics Inc. is a next-generation viable cell bone matrix processed using a proprietary method optimized to protect and preserve the health of native bone cells to potentially enhance new bone formation. It contains cancellous bone particles as well as demineralized cortical bone fibers and particles, delivering the necessary components for bone formation along with excellent handling and cohesive properties. “The moldable and cohesive handling properties of ViBone Moldable are excellent,” said Dr. Crowl and added, “with this, I am able to pack the disc space more densely compared to the other available bone graft options which increases my confidence that the interbody space is well packed and primed for fusion.”
 
“We are excited about the commercial launch and the first clinical use of ViBone Moldable,” said Terry Rich, president and CEO of Surgalign Holdings. “With this addition we have strengthened Surgalign’s biologics portfolio to better serve our surgeon customers and patients. As we introduce new, advanced biologic products to our portfolio, we are well positioned to grow our business and provide better procedurally integrated products in each operating room.”